Thyroid disorders in Programmed Death-1 inhibitors treated patients: is previous therapy with Tyrosine Kinase Inhibitors a predisposing factor?
Programmed Death 1 (PD-1) inhibitors are frequently associated with thyroid-related adverse events (TAEs), but many aspects remain unclear. This study aims to evaluate the incidence and characteristics of such events and to find any predictive factor for its development. We retrospectively analyzed data from patients with advanced solid tumors (non small cell lung carcinoma, renal cell carcinoma, metastatic melanoma) treated with PD-1 inhibitors (nivolumab, pembrolizumab) in Oncology Unit B, Policlinico Umberto I of Rome, from June 2015 to December 2018. All patients underwent baseline thyroid function evaluations repeated monthly. The cohort consisted of 126 patients (66.7% male, mean age 66.4±9.7 years). 107 received nivolumab, 19 pembrolizumab. Twenty-three percent of patients experienced TAEs (mainly CTCAE grade 1), with hypothyroidism in 15.1% (subclinical: 11.9%, overt: 3.2%) and hyperthyroidism in 8.0% (subclinical: 4.8%, overt: 3.2%). Median time to TAE onset was 8.7±6.8 weeks (10.4±7.6 weeks for hypothyroidism, 5.4±3.0 weeks for hyperthyroidism). Most TAEs (89.7%) appeared within the first three months, none after eight months. Most hypothyroid patients (63.2%) had previously been treated with a tyrosine-kinase inhibitor (TKI). Logistic regression analysis showed that pre-treatment with a TKI was a major predisposing factor for the development of hypothyroidism (OR 9.2, 95% CI: 1.4-59.9, p=0.020). TAEs are common during anti-PD-1 therapy and usually occur within the first three months of treatment. This is the first study evaluating the impact of previous oncologic therapies on TAEs, identifying TKI as a major risk factor for the development of hypothyroidism in patients treated with anti-PD-1.